Leukemia

September 30, 2021
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, September 2021

A focus on leukemia trials; an update regarding advanced practice providers; two important topics related to patient communication
September 30, 2021

Now Enrolling: Phase II of EA9152 for Acute Lymphoblastic Leukemia

This phase Ib/II study is testing the effects and safety of venetoclax in combination with liposomal vincristinein patients with B-ALL or T-ALL
September 30, 2021
Patient and doctor talking

Trial Spotlight: Selina Luger on the PrE0905 Study for FLT3 Mutated Acute Myeloid Leukemia

This phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
March 31, 2021
Female doctor consulting with older male patient

Trial Spotlight: Amer Zeidan on the BLAST MRD CML 1 Study for Chronic Myeloid Leukemia

The EA9171 phase II trial aims to determine if adding pembrolizumab immunotherapy to standard-of-care TKI therapy helps more patients achieve undetectable minimal residual disease and allows them to discontinue TKI therapy
December 14, 2020
Clipboard and laptop

Now Enrolling: ECOG-ACRIN Opened Five New Trials in October

The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
January 14, 2020

Institution Spotlight: Fox Chase Cancer Center

A Standing Main Member of ECOG-ACRIN since 1971